Takeda Partners with Sosei Heptares on GPCR Targets

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)

Published: 7 Aug-2019

DOI: 10.3833/pdr.v2019.i8.2448     ISSN: 1756-7874

Section: Research & Development



Reflecting its therapeutic focus on gastroenterology, Takeda Pharmaceutical has agreed to a multi-target alliance with Sosei Heptares to discover, develop and commercialise therapeutics that modulate G protein-coupled receptors (GPCR) for up to US$1...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details